When Is High HDL Good and When Is It Bad?

Start with what your HDL number can and can't tell you. If it's in the 50s to 70s and your LDL, non-HDL cholesterol, apoB, triglycerides, blood pressure, and blood sugar are all in good shape, a high HDL can fit a healthy metabolic profile, and there's nothing to chase. What has changed is how we read the top of the range. Once HDL climbs past about 80 to 90, several cohorts stop showing benefit and report higher cardiovascular events, all-cause death, or both. That doesn't make a single high reading dangerous. It means a very high HDL is a reason to look harder at the rest of your risk, not a reason to relax.

The good-cholesterol story holds only in the middle

For decades the assumption was simple: the higher your HDL, the better. The relationship is not a clean straight line. In many cohorts it is U-shaped, with higher risk at low HDL and again at very high HDL. A 2025 NHANES analysis of 51,235 US adults found the lowest all-cause mortality in the 50 to 59 mg/dL range. Compared with that group, people at 80 mg/dL or above had about a quarter more all-cause mortality and about a fifth more cardiovascular mortality, and the largest excess was in non-cardiovascular deaths such as cancer and respiratory disease. In two Copenhagen cohorts, lowest all-cause mortality was around 73 mg/dL in men and 93 mg/dL in women, with mortality rising only at more extreme levels: about 97 mg/dL or higher in men and 135 mg/dL or higher in women. A Chinese cohort of more than 3.3 million adults found the lowest all-cause mortality at 50 to 79 mg/dL, though its follow-up ran under four years. These are observational findings, and part of the excess at very high HDL likely reflects confounding or reverse causation, including alcohol use, liver disease, and other illness, rather than HDL itself. Low HDL still predicts higher risk in many settings. Very high HDL can too, which is the part most lab reports and most people miss.

Where the line sits depends on who you are

The concerning threshold isn't the same for everyone. In some datasets, including the UK Biobank, the excess risk at very high HDL is more pronounced in men. The sex pattern is not consistent: NHANES found the U-shape in both sexes, and a post hoc analysis of the SPRINT trial linked HDL above 80 mg/dL with lower cardiovascular risk than very low HDL, not higher. Context matters too: established coronary disease, type 2 diabetes, hypertension, and heavy alcohol use can all make a high HDL less reassuring. In a pooled Japanese analysis, HDL of 90 mg/dL or above was tied to more than double the atherosclerotic cardiovascular death rate, and the signal was stronger among current drinkers. The point is not that HDL causes the excess risk. Very high HDL can come from alcohol use, overactive thyroid, or genetic variants, and it can coexist with liver, inflammatory, or metabolic disease that changes how HDL behaves. Mendelian randomization work also found that some inherited HDL-raising variants do not reliably lower heart attack risk, so HDL-C level alone is not proof of protection.

Trying to raise HDL doesn't work

The strongest evidence that HDL is context rather than cause comes from trying to change it. Niacin, fibrates, and CETP inhibitors all raise HDL. Evacetrapib, for example, raised HDL by more than 100 percent and lowered LDL substantially, yet did not lower cardiovascular events. In statin-treated adults, meta-analyses found that these HDL-targeted drugs did not reduce death or stroke. The one modest signal, fewer heart attacks, came mostly from fibrates and tracked with their LDL lowering rather than HDL raising. The clearest loss of benefit once statins were on board was with niacin, whose earlier reduction in heart attacks disappeared in statin-treated patients. Anacetrapib, the single CETP inhibitor trial with a positive coronary-event result, also lowered non-HDL cholesterol and apoB-containing particles, making the benefit much more plausibly about particle lowering than HDL raising. In 2016, the FDA withdrew approvals for using niacin extended-release and fenofibric acid delayed-release products alongside statins to raise HDL and lower triglycerides, because drug-induced HDL or triglyceride changes no longer supported cardiovascular event reduction in statin-treated patients. HDL feeds into risk calculators, but it is not a treatment target, and European guidance warns that HDL above about 90 mg/dL should not be read as protection in risk prediction.

What actually carries the risk

The numbers worth acting on are LDL cholesterol, non-HDL cholesterol, apoB, and triglycerides, alongside blood pressure and glucose. LDL-C, non-HDL-C, and apoB are the clearest measures of atherogenic particle burden. These are all things you can check directly, and they are where a high HDL either earns its reassurance or fails to. A high HDL paired with low LDL, low apoB, normal triglycerides, normal blood pressure, and normal glucose is a coherent low-risk picture. The same HDL paired with high apoB, diabetes, high blood pressure, high triglycerides, heavy alcohol use, or inflammation is not reassuring. On the atherogenic side, lipid guidance focuses treatment thresholds and goals on LDL-C, non-HDL-C, and apoB, while European guidance treats HDL above about 90 as a warning that the usual risk math may no longer apply.

High HDL is good when it reflects a healthy overall lipid and metabolic profile. It is bad evidence when it's used to ignore LDL, non-HDL cholesterol, apoB, triglycerides, blood pressure, glucose, alcohol, or inflammation, because the highest HDL numbers don't reliably mean lower risk. What would change this conclusion is a trial showing that improving a defined HDL function, or safely lowering risk in people with very high HDL independent of apoB, non-HDL cholesterol, and LDL, prevents heart attacks or deaths. Until that exists, respect the atherogenic particle burden, not the trophy on the report.